In addition, inhibiting the CAMK2/CREB1 pathway resensitized MDR ovarian cancer cells to not only doxorubicin but also paclitaxel and topotecan, which are clinically employed to treat ovarian cancer (48). Here, CREB1 is linked to ovarian carcinoma.